GlaxoSmithKline has acquired Swiss vaccine developer Okairos for €250 million in cash. The privately held firm was spun out of Merck & Co in 2007.
GlaxoSmithKline has acquired Swiss vaccine developer Okairos for €250 million in cash. The privately held firm was spun out of Merck & Co in 2007.
Okairos' founders, Riccardo Cortese and his team, were also the founders of Istituto di Ricerche di Biologia Molecolare
Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.
J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.
Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.
The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.
Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.
